Epizyme Presents Preclinical Data on Novel G9a Program and Introduces Next Drug Development Candidate at the American Society of ...
CAMBRIDGE, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage company developing novel epigenetic therapies, announced today new preclinical data from its novel G9a program for sickle cell disease (SCD). The data were …